Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 1062

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 11
Chunk 1062
---
 the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

Item
16. Form 10–K Summary

None.

92

SIGNATURES

Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

    CONDUIT
    PHARMACEUTICALS INC.

    Date:
    March 28, 2025
    By:
    /s/
    David Tapolczay

    Name:
    David
    Tapolczay

    Title:
    Chief
    Executive Officer

POWER
OF ATTORNEY

KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Tapolczay and James Bligh,
and each of them, as his or her attorneys-in-fact, with the power of substitution, for him or her in any and all capacities, to sign
any amendments to this report, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities
and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, and each of them, or his or her substitute
or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

    Signature
     
    Title
     
    Date

    /s/
    David Tapolczay
     
    Chief
    Executive Officer and Director
     
    March
    28, 2025
  
    David
    Tapolczay
     
    (Principal
    Executive Officer)

    /s/
    James Bligh
     
    Interim
    Chief Financial Officer
     
    March
    28, 2025
  
    Jamie
    Bligh
     
    (Principal
    Financial Officer and Principal Accounting Officer)

    /s/
    Freda Lewis-Hall
     
    Director
    and Chairperson of the Board of Directors
     
    March
    28, 2025
  
    Freda
    Lewis-Hall

    /s/